Inducibility of life-threatening ventricular arrhythmias is related to maximum left ventricular thickness and clinical markers of sudden cardiac death in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the α-tropomyosin gene

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 1, 2004, Pages 91-99

  Hedman, A ^a   Hartikainen, J ^a   Vanninen, E ^a   Laitinen, T ^a   Jaaskelainen P ^a   Laakso, M ^a   Peuhkurinen, K ^a   Kuusisto, J ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Genetics; Hypertrophic cardiomyopathy; Left ventricular hypertrophy; Programmed ventricular stimulation; Risk marker; Sudden cardiac death

Indexed keywords

ASPARAGINE; ASPARTIC ACID; TROPOMYOSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EXERCISE; FAMILY HISTORY; FEMALE; GENE MUTATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART STIMULATION; HEART VENTRICLE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PHENOTYPE; PRIORITY JOURNAL; SUDDEN DEATH; SYNCOPE; SYSTOLIC BLOOD PRESSURE;

EID: 0345743538     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2003.10.003     Document Type: Article

References (23)

1. Maron B.J. Hypertrophic cardiomyopathy. JAMA. 287:2002;1308-1320.
2. Elliot P.M., Poloniecki J., Dickie S., Sharma S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 36:2000;2212-2218.
3. Fananapazir L., Tracy C.M., Leon M.B., et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. Circulation. 80:1989;1259-1268.
4. Watson R.M., Schwartz J.L., Maron B.J., Tucker E., Rosing D., Josephson M.E. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy and high risk for sudden cardiac death. J Am Coll Cardiol. 10:1987;761-774.
5. Fananapazir L., Chang A.C., Epstein S.E., McAreavery D. Prognostic determinants in hypertrophic cardiomyopathy. Circulation. 86:1992;730-740.
6. Spirito P., Seidman C., McKenna W.J., Maron B.J. The management of hypertrophic cardiomyopathy. New Engl J Med. 336:(11):1997;775-785.
7. Jääskeläinen P., Soranta M., Miettinen R., et al. The cardiac -myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J Am Coll Cardiol. 32:1998;1709-1716.
8. Coviello D.A., Maron B.J., Spirito P., et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alfa-tropomyosin gene. J Am Coll Cardiol. 29:1997;635-640.
9. McKenna W., Spirito P., Desnos M., Dubourg O., Komajda M. Experience from clinical genetics in hypertrophic cariomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 77:1977;130-132.
10. Jääskeläinen P., Miettinen R., Kärkkäinen P., Toivonen L., Laakso M., Kuusisto J. enetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. Ann Med. 2003;. [in press].
11. Sahn D.J., De Maria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 58:1978;1072-1083.
12. Zhu D.W.X., Sun H., Hill R., Roberts R. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patient with hypertrophic cardiomyopathy. PACE. 21:1998;299-302.
13. Atiga W.L., McAreavey D., Epstein N.D., Fananapazir L. Risk stratification of asymptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 23:1994;110A.
14. Behr E.R., Elliott P., McKenna W.J. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev. 6:(4):2002;482-486.
15. Maron B.J., Shen W.-K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. New Engl J Med. 342:2000;365-373.
16. Berul C.I., McConnell B.K., Wakimoto H., et al. Ventricular arrhythmia vulnerability in cardiomyopathic mice with homozygous mutant myosin-binding protein C gene. Circulation. 104:2001;2734-2739.
17. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined ventricular mass in the Framingham Heart Study. New Engl J Med. 323:(24):1990;1706-1707.
18. Spirito P., Bellone P., Harris K.M., Bernabo P., Bruzzi P., Maron B.J. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. New Engl J Med. 342:2000;1778-1785.
19. Elliot P.M., Blanes J.R.G., Mahon N.G., Poloniecki J.D., McKenna W.J. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 357:2001;420-424.
20. Jansson K., Dahlström U., Karlsson E., Nylander E., Walfridsson H., Sonnhag C. The value of exercise test, Holter monitoring, and programmed electrical stimulation in detection of ventricular arrhythmias in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 13:(10):1990;1261-1267.
21. Sipola P., Lauerma K., Husso-Saastamoinen M., et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and Asp175Asn mutation of the -tropomyosin gene. Radiology. 226:(1):2003;129-137.
22. Arad M., Seidman J.G., Seidman C.E. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet. 11:(20):2002;2499-2506.
23. Olivotto I., Gistri R., Petrone P., Pedemonte E., Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 41:2003;315-321.